Sandoz Pioneers Posaconazole And Silodosin In Canada
After Canadian Court Rules In Its Favour For Patent Litigation
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
You may also be interested in...
A favorable court ruling has allowed Sandoz Canada to launch the first generic version of Roche’s Esbriet to treat idiopathic pulmonary fibrosis.
Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.
Sandoz has succeeded in convincing a Canadian court that its generic version of Rapaflo does not infringe a formulation patent for silodosin capsules, although the firm’s invalidity claims fell on deaf ears.